Cancer patients & supplements
This article was originally published in The Tan Sheet
Executive SummaryIncreased alternative medicine education for health care providers serving cancer patients is necessary due to high prevalence of supplement use among cancer patients, Ruth Patterson, PhD, Fred Hutchinson Cancer Center, et al., conclude from data obtained in survey appearing in the September Journal of Alternative & Complementary Medicine. Phone interviews of 356 cancer patients selected from the Washington State Cancer Surveillance System indicated 64.6% take supplements, Patterson et al. find. Users spent an average of $68 on alternative medicine per year and were "more likely to be female, younger and more educated than non-users," researchers note. Study limitations included lack of ethnic diversity among respondents, inability to ensure consistent behavior among respondents and non-respondents...
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.